Christine B Sethna1,2, Derek K Ng3, Shuai Jiang3, Jeff Saland4, Bradley A Warady5, Susan Furth6, Kevin E Meyers6. 1. Division of Pediatric Nephrology, Cohen Children's Medical Center of New York, New Hyde Park, NY, USA. csethna@northwell.edu. 2. Division of Nephrology, 269-01 76th Avenue, New Hyde Park, NY, 11040, USA. csethna@northwell.edu. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Division of Pediatric Nephrology Mt. Sinai Medical Center, New York, NY, USA. 5. Division of Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, MO, USA. 6. Division of Pediatric Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Abstract
BACKGROUND: The aims were to compare the cardiovascular disease (CVD) risk among children with chronic kidney disease (CKD) secondary to focal segmental glomerulosclerosis (FSGS) with the CVD risk of children with CKD due to other diagnoses. METHODS: Casual blood pressure (BP), ambulatory blood pressure monitoring (APBM), echocardiogram, lipids, carotid intima medial thickness (cIMT), and uric acid obtained from participants in the Chronic Kidney Disease in Children (CKiD) cohort were analyzed longitudinally. Seventy-nine children with FSGS (FSGS-CKD) were compared to 196 children with non-FSGS glomerular disease (GDO-CKD) and 616 children with non-glomerular disease (NG-CKD). RESULTS: At baseline, FSGS-CKD (median 14 years) had ambulatory hypertension (24.6%), masked hypertension (46.2%), left ventricular hypertrophy (LVH) (26.3%), and dyslipidemia (60.0%). In adjusted models, FSGS-CKD had higher systolic BP z-score (0.52 vs 0.11 and 0.23, p = 0.002 and 0.02), triglycerides (133 vs 109 and 102 mg/dl, p = 0.007 and < 0.001), and non-high density lipoprotein (144 vs 132 and 119 mg/dl, p = 0.07 and < 0.001) at baseline when compared to GDO-CKD and NG-CKD, respectively. Left ventricular mass index (LVMI) (36.0 vs 31.7 g/m2.7, p < 0.001) and the odds of LVH (OR 3.38, 95% CI 1.42, 8.08) at baseline were greater in FSGS-CKD compared to NG-CKD. Adjusted longitudinal analysis showed that FSGS-CKD had a faster decline in LVMI than NG-CKD, and FSGS-CKD had a faster increase in uric acid compared to both groups. CONCLUSIONS: Children with CKD due to FSGS had a relatively high prevalence of CVD risk factors. FSGS was associated with greater CVD risk when compared to other CKD diagnoses.
BACKGROUND: The aims were to compare the cardiovascular disease (CVD) risk among children with chronic kidney disease (CKD) secondary to focal segmental glomerulosclerosis (FSGS) with the CVD risk of children with CKD due to other diagnoses. METHODS: Casual blood pressure (BP), ambulatory blood pressure monitoring (APBM), echocardiogram, lipids, carotid intima medial thickness (cIMT), and uric acid obtained from participants in the Chronic Kidney Disease in Children (CKiD) cohort were analyzed longitudinally. Seventy-nine children with FSGS (FSGS-CKD) were compared to 196 children with non-FSGS glomerular disease (GDO-CKD) and 616 children with non-glomerular disease (NG-CKD). RESULTS: At baseline, FSGS-CKD (median 14 years) had ambulatory hypertension (24.6%), masked hypertension (46.2%), left ventricular hypertrophy (LVH) (26.3%), and dyslipidemia (60.0%). In adjusted models, FSGS-CKD had higher systolic BP z-score (0.52 vs 0.11 and 0.23, p = 0.002 and 0.02), triglycerides (133 vs 109 and 102 mg/dl, p = 0.007 and < 0.001), and non-high density lipoprotein (144 vs 132 and 119 mg/dl, p = 0.07 and < 0.001) at baseline when compared to GDO-CKD and NG-CKD, respectively. Left ventricular mass index (LVMI) (36.0 vs 31.7 g/m2.7, p < 0.001) and the odds of LVH (OR 3.38, 95% CI 1.42, 8.08) at baseline were greater in FSGS-CKD compared to NG-CKD. Adjusted longitudinal analysis showed that FSGS-CKD had a faster decline in LVMI than NG-CKD, and FSGS-CKD had a faster increase in uric acid compared to both groups. CONCLUSIONS:Children with CKD due to FSGS had a relatively high prevalence of CVD risk factors. FSGS was associated with greater CVD risk when compared to other CKD diagnoses.
Authors: Wyman W Lai; Tal Geva; Girish S Shirali; Peter C Frommelt; Richard A Humes; Michael M Brook; Ricardo H Pignatelli; Jack Rychik Journal: J Am Soc Echocardiogr Date: 2006-12 Impact factor: 5.251
Authors: Mark M Mitsnefes; Gina M Barletta; Ian G Dresner; Deepa H Chand; Denis Geary; Jen-Jar Lin; Hiren Patel Journal: Pediatr Nephrol Date: 2006-06-29 Impact factor: 3.714
Authors: Tammy M Brady; Michael F Schneider; Joseph T Flynn; Christopher Cox; Joshua Samuels; Jeffrey Saland; Colin T White; Susan Furth; Bradley A Warady; Mark Mitsnefes Journal: Clin J Am Soc Nephrol Date: 2012-09-13 Impact factor: 8.237
Authors: Christine B Sethna; Kevin E C Meyers; Laura H Mariani; Kevin J Psoter; Crystal A Gadegbeku; Keisha L Gibson; Tarak Srivastava; Matthias Kretzler; Tammy M Brady Journal: Hypertension Date: 2017-06-26 Impact factor: 10.190
Authors: Michelle R Denburg; Heidi J Kalkwarf; Ian H de Boer; Martin Hewison; Justine Shults; Babette S Zemel; David Stokes; Debbie Foerster; Benjamin Laskin; Anthony Ramirez; Mary B Leonard Journal: Pediatr Nephrol Date: 2013-06-02 Impact factor: 3.714
Authors: Rae-Ellen W Kavey; Vivek Allada; Stephen R Daniels; Laura L Hayman; Brian W McCrindle; Jane W Newburger; Rulan S Parekh; Julia Steinberger Journal: J Cardiovasc Nurs Date: 2007 May-Jun Impact factor: 2.083
Authors: Robert P Woroniecki; Derek K Ng; Sophie Limou; Cheryl A Winkler; Kimberly J Reidy; Mark Mitsnefes; Matthew G Sampson; Craig S Wong; Bradley A Warady; Susan L Furth; Jeffrey B Kopp; Frederick J Kaskel Journal: Front Pediatr Date: 2016-11-17 Impact factor: 3.418
Authors: Denver D Brown; Jennifer Roem; Derek K Ng; Kimberly J Reidy; Juhi Kumar; Matthew K Abramowitz; Robert H Mak; Susan L Furth; George J Schwartz; Bradley A Warady; Frederick J Kaskel; Michal L Melamed Journal: Clin J Am Soc Nephrol Date: 2020-05-28 Impact factor: 8.237
Authors: Alanna Strong; Michael E March; Christopher J Cardinale; Sophia E Kim; Jamie Merves; Hilary Whitworth; Leslie Raffini; Christopher Larosa; Lawrence Copelovitch; Cuiping Hou; Diana Slater; Courtney Vaccaro; Deborah Watson; Elaine H Zackai; Jeffrey Billheimer; Hakon Hakonarson Journal: Am J Med Genet A Date: 2021-10-15 Impact factor: 2.578
Authors: Paras P Shah; Tammy M Brady; Kevin E C Meyers; Michelle M O'Shaughnessy; Keisha L Gibson; Tarak Srivastava; Jarcy Zee; Daniel Cattran; Katherine R Tuttle; Crystal Gadegbeku; Dorey Glenn; Vimal Derebail; Abigail Smith; Chia-Shi Wang; Brenda W Gillespie; Markus Bitzer; Christine B Sethna Journal: Nephron Date: 2021-03-05 Impact factor: 2.847